Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Uniqure Ord Shs
(NQ:
QURE
)
5.790
-0.050 (-0.86%)
Streaming Delayed Price
Updated: 1:49 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Uniqure Ord Shs
< Previous
1
2
3
4
5
6
Next >
Match Stock, Tandem Diabetes Lead Big Movers Due To S&P Index Changes
September 07, 2021
Match will join the S&P 500 and Tandem Diabetes the S&P MidCap 400. UniQure enters the SmallCap 600.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
23 Stocks Moving in Tuesday's Pre-Market Session
September 07, 2021
Gainers IronNet, Inc. (NYSE: IRNT) rose 89.7% to $31.61 in pre-market trading after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares rose 36.6% to $4.37 in pre-market...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 15, 2021
During the morning session on Thursday, 152 stocks hit new 52-week lows. Interesting Points: TotalEnergies (NYSE:TTE) was the biggest company by market cap to set a new 52...
Via
Benzinga
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 19, 2021
Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows. Noteworthy Points: The largest company by market cap to set a new 52-week...
Via
Benzinga
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
July 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
July 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 13, 2021
Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows. Interesting Highlights: Marqeta (NASDAQ:MQ) was the largest company by market cap to set a new 52-...
Via
Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels
June 22, 2021
UniQure N.V. (NASDAQ: QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia B. Data...
Via
Benzinga
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
June 22, 2021
UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...
Via
Benzinga
DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged
May 27, 2021
The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...
Via
Benzinga
Why Moderna, uniQure And Novavax Are Moving Today
May 06, 2021
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V. (NASDAQ: QURE) and Novavax, Inc. (NASDAQ: NVAX) were among the biggest movers among biopharma stocks Thursday. Moderna Slides On Q1...
Via
Benzinga
58 Biggest Movers From Yesterday
April 27, 2021
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial...
Via
Benzinga
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
April 26, 2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR...
Via
Benzinga
38 Stocks Moving In Monday's Mid-Day Session
April 26, 2021
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug...
Via
Benzinga
Uniqure Stock Pops After FDA Says It Can Resume Gene Therapy Tests
April 26, 2021
The Food and Drug Administration said Monday that Uniqure can resume testing its hemophilia B gene therapy, and QURE stock popped.
Via
Investor's Business Daily
Exposures
Product Safety
Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy
April 26, 2021
Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new...
Via
Benzinga
Exposures
Product Safety
UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program
April 26, 2021
The FDA has removed the clinical hold on uniQure NV's (NASDAQ: QURE) hemophilia B gene therapy program after determining the company had...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 26, 2021
Gainers Ocugen (NASDAQ:OCGN) shares rose 13.81% to $10.96 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Advaxis...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.